Literature DB >> 23174883

Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype.

A Rio-Machin1, B I Ferreira, T Henry, G Gómez-López, X Agirre, S Alvarez, S Rodriguez-Perales, F Prosper, M J Calasanz, J Martínez, R Fonseca, J C Cigudosa.   

Abstract

Currently, multiple myeloma (MM) patients are broadly grouped into a non-hyperdiploid (nh-MM) group, highly enriched for IgH translocations, or into a hyperdiploid (h-MM) group, which is typically characterized by trisomies of some odd-numbered chromosomes. We compared the micro RNA (miRNA) expression profiles of these two groups and we identified 16 miRNAs that were downregulated in the h-MM group, relative to the nh-MM group. We found that target genes of the most differentially expressed miRNAs are directly involved in the pathogenesis of MM; specifically, the inhibition of hsa-miR-425, hsa-miR-152 and hsa-miR-24, which are all downregulated in h-MM, leads to the overexpression of CCND1, TACC3, MAFB, FGFR3 and MYC, which are the also the oncogenes upregulated by the most frequent IgH chromosomal translocations occurring in nh-MM. Importantly, we showed that the downregulation of these specific miRNAs and the upregulation of their targets also occur simultaneously in primary cases of h-MM. These data provide further evidence on the unifying role of cyclin D pathways deregulation as the key mechanism involved in the development of both groups of MM. Finally, they establish the importance of miRNA deregulation in the context of MM, thereby opening up the potential for future therapeutic approaches based on this molecular mechanism.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23174883     DOI: 10.1038/leu.2012.302

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  18 in total

1.  Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients.

Authors:  Nathaniel H Fleming; Judy Zhong; Inês Pires da Silva; Eleazar Vega-Saenz de Miera; Bobbi Brady; Sung Won Han; Doug Hanniford; Jinhua Wang; Richard L Shapiro; Eva Hernando; Iman Osman
Journal:  Cancer       Date:  2014-08-25       Impact factor: 6.860

Review 2.  DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment.

Authors:  Claire Gourzones-Dmitriev; Alboukadel Kassambara; Surinder Sahota; Thierry Rème; Jérôme Moreaux; Pascal Bourquard; Dirk Hose; Philippe Pasero; Angelos Constantinou; Bernard Klein
Journal:  Cell Cycle       Date:  2013-08-09       Impact factor: 4.534

3.  Identification of key genes and construction of microRNA-mRNA regulatory networks in multiple myeloma by integrated multiple GEO datasets using bioinformatics analysis.

Authors:  Hongyu Gao; Huihan Wang; Wei Yang
Journal:  Int J Hematol       Date:  2017-03-18       Impact factor: 2.490

Review 4.  Staging and prognostication of multiple myeloma.

Authors:  Rafael Fonseca; Jorge Monge; Meletios A Dimopoulos
Journal:  Expert Rev Hematol       Date:  2014-02       Impact factor: 2.929

5.  Downregulation of MicroRNA-152 contributes to high expression of DKK1 in multiple myeloma.

Authors:  Yinyin Xu; Bingda Chen; Suraj K George; Beizhong Liu
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

Review 6.  Association of Chromosomal Translocation and MiRNA Expression with The Pathogenesis of Multiple Myeloma.

Authors:  Najmaldin Saki; Saeid Abroun; Saeideh Hajizamani; Fakher Rahim; Mohammad Shahjahani
Journal:  Cell J       Date:  2014-05-25       Impact factor: 2.479

7.  Epigenetic regulation of thyroid hormone receptor beta in renal cancer.

Authors:  Anna Wojcicka; Agnieszka Piekielko-Witkowska; Hanna Kedzierska; Beata Rybicka; Piotr Poplawski; Joanna Boguslawska; Adam Master; Alicja Nauman
Journal:  PLoS One       Date:  2014-05-21       Impact factor: 3.240

8.  Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors.

Authors:  J Moreaux; T Reme; W Leonard; J-L Veyrune; G Requirand; H Goldschmidt; D Hose; B Klein
Journal:  Br J Cancer       Date:  2013-07-18       Impact factor: 7.640

Review 9.  Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.

Authors:  Jahangir Abdi; Guoan Chen; Hong Chang
Journal:  Oncotarget       Date:  2013-12

Review 10.  MicroRNA: important player in the pathobiology of multiple myeloma.

Authors:  Chonglei Bi; Wee Joo Chng
Journal:  Biomed Res Int       Date:  2014-06-03       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.